<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02666365</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00003845</org_study_id>
    <nct_id>NCT02666365</nct_id>
  </id_info>
  <brief_title>Continuous v Bolus Infusion of Cefazolin During Ventral Hernia Repair</brief_title>
  <official_title>Pharmacokinetic Comparison of Cefazolin Redosing Strategy for Surgical Prophylaxis. Bolus Dose vs Continuous Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients undergoing an elective ventral hernia repair will be randomly assigned to receive
      either bolus infusion or continuous infusion of the cefazolin as the prophylactic antibiotic.
      The blood concentrations of unbound cefazolin would be measured in their blood samples and
      the levels compared within the two groups with respect to their minimal inhibitory
      concentration (MIC) value.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who will be undergoing elective ventral hernia repair will be potential candidates
      for this study. Once identified, the surgical team will approach the participant for consent
      and inclusion in the study. On the day of surgery, the subjects will be assigned to either
      the Bolus Group (CB) or Continuous Infusion Group (CI) according to a randomly generated
      assignment procedure. During the procedure, the dose of prophylactic Cefazolin will be given
      an hour before surgery and will be administered in accordance to group assignment. Subjects
      in the CB will receive bolus infusions of Cefazolin every 4 hours till the end of surgery.
      Subjects in the CI group will receive an initial bolus injection of Cefazolin followed by a
      continuous infusion till the closure of skin incision. Blood samples will be taken during
      surgery at t=0, 15, 30 and 60 minutes and every hour following till the end of surgery or 6
      hours (whichever comes sooner)
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Investigator decided not to proceed.
  </why_stopped>
  <start_date type="Anticipated">March 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in Area Under Curve (AUC) of Cefazolin plasma concentration and minimum inhibitory concentration (MIC) in both treatment arms</measure>
    <time_frame>First four hours</time_frame>
    <description>After blood sample collection is completed samples will be analyzed for plasma concentrations of cefazolin. This concentration will be compared with the standard minimum inhibitory concentration of Cefazolin. It is expected that the difference between AUC and MIC in the continuous infusion group will be higher than the bolus infusion group during the first four hours of surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in AUC of plasma concentration between the two regimens for the entire duration of surgery</measure>
    <time_frame>Duration of surgery</time_frame>
    <description>After blood sample collection is completed samples will be analyzed for plasma concentrations of cefazolin. This concentration will be compared with the standard minimum inhibitory concentration of Cefazolin. It is expected that the difference between AUC and MIC in the continuous infusion group will be higher than the bolus infusion group for the entire duration of surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of cefazolin administered during the surgery</measure>
    <time_frame>Duration of surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of cefazolin administered during the first 24 hours</measure>
    <time_frame>24 hours after the beginning of surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Surgical Site Infections</condition>
  <arm_group>
    <arm_group_label>Bolus infusion of Cefazolin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects undergoing a ventral hernia repair in this arm of the study will receive the surgical prophylactic, cefazolin, in a bolus infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous Infusion of Cefazolin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects undergoing a ventral hernia repair in this arm of the study will receive the surgical prophylactic, cefazolin, in a continuous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bolus infusion of Cefazolin</intervention_name>
    <description>Subjects in the bolus infusion arm of the study will receive bolus infusions of cefazolin throughout the surgical procedure</description>
    <arm_group_label>Bolus infusion of Cefazolin</arm_group_label>
    <other_name>Bolus infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Continuous infusion of Cefazolin</intervention_name>
    <description>Subjects in the continuous infusion arm of the study will receive a continuous infusion of the cefazolin throughout the surgical procedure</description>
    <arm_group_label>Continuous Infusion of Cefazolin</arm_group_label>
    <other_name>Continuous infusion</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 years

          -  Elective open Ventral hernia repair in CDC class one (clean) cases

          -  Planned operative time greater than 4 Hours

          -  Planned routine administration of cefazolin for pre-op prophylaxis

          -  No history of MRSA

        Exclusion Criteria:

          -  Patients unable to give informed consent

          -  Allergy to cephalosporins

          -  Pre-existing documented infection or ostomy (class II-IV wounds)

          -  Received cefazolin within 24 hours before surgery

          -  Creatinine clearance &lt; 30 ml/min

          -  Upstaging of wound class intra-op that results in the administration of additional
             antibiotics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kunal Karamchandani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <reference>
    <citation>MILES AA, MILES EM, BURKE J. The value and duration of defence reactions of the skin to the primary lodgement of bacteria. Br J Exp Pathol. 1957 Feb;38(1):79-96.</citation>
    <PMID>13413084</PMID>
  </reference>
  <reference>
    <citation>Lee FM, Trevino S, Kent-Street E, Sreeramoju P. Antimicrobial prophylaxis may not be the answer: Surgical site infections among patients receiving care per recommended guidelines. Am J Infect Control. 2013 Sep;41(9):799-802. doi: 10.1016/j.ajic.2012.11.021. Epub 2013 Mar 13.</citation>
    <PMID>23489739</PMID>
  </reference>
  <reference>
    <citation>Hawn MT, Vick CC, Richman J, Holman W, Deierhoi RJ, Graham LA, Henderson WG, Itani KM. Surgical site infection prevention: time to move beyond the surgical care improvement program. Ann Surg. 2011 Sep;254(3):494-9; discussion 499-501. doi: 10.1097/SLA.0b013e31822c6929.</citation>
    <PMID>21817889</PMID>
  </reference>
  <reference>
    <citation>Stulberg JJ, Delaney CP, Neuhauser DV, Aron DC, Fu P, Koroukian SM. Adherence to surgical care improvement project measures and the association with postoperative infections. JAMA. 2010 Jun 23;303(24):2479-85. doi: 10.1001/jama.2010.841.</citation>
    <PMID>20571014</PMID>
  </reference>
  <reference>
    <citation>Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, Fish DN, Napolitano LM, Sawyer RG, Slain D, Steinberg JP, Weinstein RA; American Society of Health-System Pharmacists (ASHP); Infectious Diseases Society of America (IDSA); Surgical Infection Society (SIS); Society for Healthcare Epidemiology of America (SHEA). Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt). 2013 Feb;14(1):73-156. doi: 10.1089/sur.2013.9999. Epub 2013 Mar 5.</citation>
    <PMID>23461695</PMID>
  </reference>
  <reference>
    <citation>Adembri C, Ristori R, Chelazzi C, Arrigucci S, Cassetta MI, De Gaudio AR, Novelli A. Cefazolin bolus and continuous administration for elective cardiac surgery: improved pharmacokinetic and pharmacodynamic parameters. J Thorac Cardiovasc Surg. 2010 Aug;140(2):471-5. doi: 10.1016/j.jtcvs.2010.03.038. Epub 2010 Jun 8.</citation>
    <PMID>20570290</PMID>
  </reference>
  <reference>
    <citation>Trent Magruder J, Grimm JC, Dungan SP, Shah AS, Crow JR, Shoulders BR, Lester L, Barodka V. Continuous Intraoperative Cefazolin Infusion May Reduce Surgical Site Infections During Cardiac Surgical Procedures: A Propensity-Matched Analysis. J Cardiothorac Vasc Anesth. 2015 Dec;29(6):1582-7. doi: 10.1053/j.jvca.2015.03.026. Epub 2015 Mar 31.</citation>
    <PMID>26275516</PMID>
  </reference>
  <reference>
    <citation>Ferraz ÁA, Siqueira LT, Campos JM, Araújo GC, Martins Filho ED, Ferraz EM. ANTIBIOTIC PROPHYLAXIS IN BARIATRIC SURGERY: a continuous infusion of cefazolin versus ampicillin/sulbactam and ertapenem. Arq Gastroenterol. 2015 Apr-Jun;52(2):83-7. doi: 10.1590/S0004-28032015000200002.</citation>
    <PMID>26039823</PMID>
  </reference>
  <reference>
    <citation>Finan KR, Vick CC, Kiefe CI, Neumayer L, Hawn MT. Predictors of wound infection in ventral hernia repair. Am J Surg. 2005 Nov;190(5):676-81.</citation>
    <PMID>16226938</PMID>
  </reference>
  <reference>
    <citation>Dunne JR, Malone DL, Tracy JK, Napolitano LM. Abdominal wall hernias: risk factors for infection and resource utilization. J Surg Res. 2003 May 1;111(1):78-84.</citation>
    <PMID>12842451</PMID>
  </reference>
  <reference>
    <citation>Houck JP, Rypins EB, Sarfeh IJ, Juler GL, Shimoda KJ. Repair of incisional hernia. Surg Gynecol Obstet. 1989 Nov;169(5):397-9.</citation>
    <PMID>2530641</PMID>
  </reference>
  <reference>
    <citation>Kaafarani HM, Kaufman D, Reda D, Itani KM. Predictors of surgical site infection in laparoscopic and open ventral incisional herniorrhaphy. J Surg Res. 2010 Oct;163(2):229-34. doi: 10.1016/j.jss.2010.03.019. Epub 2010 Apr 1.</citation>
    <PMID>20605590</PMID>
  </reference>
  <reference>
    <citation>Blatnik JA, Krpata DM, Novitsky YW, Rosen MJ. Does a history of wound infection predict postoperative surgical site infection after ventral hernia repair? Am J Surg. 2012 Mar;203(3):370-4; discussion 374. doi: 10.1016/j.amjsurg.2011.12.001.</citation>
    <PMID>22364903</PMID>
  </reference>
  <reference>
    <citation>Buijk SE, Gyssens IC, Mouton JW, Metselaar HJ, Groenland TH, Verbrugh HA, Bruining HA. Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients. J Antimicrob Chemother. 2004 Jul;54(1):199-205. Epub 2004 Jun 2.</citation>
    <PMID>15175266</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2016</study_first_submitted>
  <study_first_submitted_qc>January 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2016</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Kunal Karamchandani</investigator_full_name>
    <investigator_title>Assistant Professor of Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>anesthesia</keyword>
  <keyword>surgical antimicrobial prophylaxis</keyword>
  <keyword>surgical site infections</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefazolin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

